New Delhi, January 20, 2018: Suven Life SciencesBSE -0.92 % has secured a product patent each from China and Sri Lankacorresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The two patents are valid through 2033 and 2032, respectively, the company said in a BSE filing according to economictimes.indiatimes.com.

“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.

According to the company, the granted claims of the patents are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Parkinson and Schizophrenia.